Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
42
REGN Quote, Financials, Valuation and Earnings
Last price:
$701.91
Seasonality move
:
10.8%
Day range:
$700.83 - $717.61
52-week range:
$693.00 - $1,211.20
Dividend yield:
0%
P/E ratio:
17.37x
P/S ratio:
5.83x
P/B ratio:
2.63x
Volume:
1.9M
Avg. volume:
900.7K
1-year change:
-16.62%
Market cap:
$77.1B
Revenue:
$13.1B
EPS (TTM):
$40.41
Analysts' Opinion
-
Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $1,053.08, Regeneron Pharmaceuticals has an estimated upside of 50.04% from its current price of $701.85.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $565.00 representing 19.5% downside risk from its current price of $701.85.
Fair Value
-
According to the consensus of 18 analysts, Regeneron Pharmaceuticals has 50.04% upside to fair value with a price target of $1,053.08 per share.
REGN vs. S&P 500
-
Over the past 5 trading days, Regeneron Pharmaceuticals has underperformed the S&P 500 by -2.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Regeneron Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Regeneron Pharmaceuticals has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Regeneron Pharmaceuticals reported revenues of $3.7B.
Earnings Growth
-
Regeneron Pharmaceuticals has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Regeneron Pharmaceuticals reported earnings per share of $11.54.
Enterprise value:
69.3B
EV / Invested capital:
2.21x
Price / LTM sales:
5.83x
EV / EBIT:
13.77x
EV / Revenue:
5.01x
PEG ratio (5yr expected):
1.14x
EV / Free cash flow:
20.88x
Price / Operating cash flow:
24.34x
Enterprise value / EBITDA:
12.60x
Gross Profit (TTM):
$11.9B
Return On Assets:
13.44%
Net Income Margin (TTM):
33.61%
Return On Equity:
17.19%
Return On Invested Capital:
16.02%
Operating Margin:
33.21%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $13.7B | $13.1B | $13.8B | $3.4B | $3.7B | |
| Gross Profit | $11.7B | $11.3B | $11.9B | $2.9B | $3.2B | |
| Operating Income | $6.5B | $4.4B | $4.1B | $1.2B | $1.2B | |
| EBITDA | $6.4B | $4.9B | $5.5B | $1.2B | $1.6B | |
| Diluted EPS | $47.43 | $35.06 | $40.41 | $8.89 | $11.54 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9.1B | $13.8B | $15.4B | $18.6B | $19.3B | |
| Total Assets | $16.1B | $23.7B | $27.7B | $32.2B | $37.4B | |
| Current Liabilities | $2.3B | $3.7B | $2.9B | $3.6B | $3.7B | |
| Total Liabilities | $6B | $6.4B | $6.2B | $7.3B | $8.1B | |
| Total Equity | $10.1B | $17.3B | $21.4B | $24.9B | $29.3B | |
| Total Debt | $2B | $2B | $2B | $2B | $2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $5.7B | $5.2B | $4.2B | $1.1B | $1.3B | |
| Cash From Investing | -$3.9B | -$5B | -$2.9B | -$496.3M | -$574.4M | |
| Cash From Financing | -$1.7B | -$1.6B | -$1.5B | -$407.3M | -$634M | |
| Free Cash Flow | $4.1B | $4.4B | $3.3B | $914.4M | $1B | |
REGN
Sector
Market Cap
$77.1B
$44.6M
Price % of 52-Week High
57.95%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
1.28%
-0.68%
1-Year Price Total Return
-16.62%
-29.09%
Beta (5-Year)
0.084
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$729.36
200-day SMA
Sell
Level
$980.92
Bollinger Bands (100)
Sell
Level
805.13 - 1140.25
Chaikin Money Flow
Buy
Level
83.9M
20-day SMA
Sell
Level
$747.95
Relative Strength Index (RSI14)
Sell
Level
27.80
ADX Line
Sell
Level
11.41
Williams %R
Buy
Level
-91.8048
50-day SMA
Sell
Level
$826.21
MACD (12, 26)
Sell
Level
-29.66
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
41.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.6719)
Buy
CA Score
(Annual)
Level (1.6072)
Buy
Beneish M-Score
(Annual)
Level (-2.44)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-4.591)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Stock Forecast FAQ
In the current month, REGN has received 12 Buy ratings 6 Hold ratings, and 0 Sell ratings. The REGN average analyst price target in the past 3 months is $1,053.08.
-
Where Will Regeneron Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Regeneron Pharmaceuticals share price will rise to $1,053.08 per share over the next 12 months.
-
What Do Analysts Say About Regeneron Pharmaceuticals?
Analysts are divided on their view about Regeneron Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Regeneron Pharmaceuticals is a Sell and believe this share price will drop from its current level to $565.00.
-
What Is Regeneron Pharmaceuticals's Price Target?
The price target for Regeneron Pharmaceuticals over the next 1-year time period is forecast to be $1,053.08 according to 18 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is REGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Regeneron Pharmaceuticals is a Buy. 12 of 18 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of REGN?
You can purchase shares of Regeneron Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Regeneron Pharmaceuticals shares.
-
What Is The Regeneron Pharmaceuticals Share Price Today?
Regeneron Pharmaceuticals was last trading at $701.91 per share. This represents the most recent stock quote for Regeneron Pharmaceuticals. Yesterday, Regeneron Pharmaceuticals closed at $701.85 per share.
-
How To Buy Regeneron Pharmaceuticals Stock Online?
In order to purchase Regeneron Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
